



2AE71



BRAWN BIOTECH LTD.

14th February 2026

The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai -400001

BSE Scrip Code: 530207
Scrip ID: BRAWN

Sub: Outcome of the Board Meeting of the Company held on 14th February 2026, and submissions of Un-Audited Financial Results for the Quarter and year to date ended 31.12.2025.

Ref: Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (SEBI Listing regulations).

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 14th February 2026 has considered and approved the Un-Audited Financial Results along with Limited Review Report by the Company's Statutory Auditor for the Quarter and year to date ended 31.12.2025, a Copy of which is enclosed herewith.

We wish to further inform you that the meeting of the board of directors commenced at 1:30 P.M. and concluded at 2:00 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You.

For and on behalf of
Brawn Biotech Limited



Priyanka Sharma
Company Secretary and Compliance Officer
Membership No.: A50385
Encl: As above



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in

...for better life



E4A32

**BRAWN BIOTECH LTD.**BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER 2025

Rs in Lacs

Sr.	Particulars	Quarter ended			Nine Months ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
a	Revenue from operations	431.26	489.10	384.48	1,500.13	1,120.57	1,346.50
b	Other Income	9.10	9.12	0.08	27.31	0.21	9.33
	Total Revenue	440.36	498.22	384.56	1,527.44	1,120.79	1,355.83
2	Expenses						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	257.63	536.48	800.26	1,281.82	1,320.05	1,638.05
c	Change in inventories of finished goods, work in progress and stock in trade	14.77	-120.52	-45.49	-0.83	-322.20	-445.04
d	Employee Benefit expenses	14.08	14.55	20.93	49.15	90.14	112.63
e	Depreciation and amortisation expenses	3.03	3.10	3.08	9.20	8.33	11.46
f	Finance Cost	0.01	0.18	0.01	0.22	0.16	0.37
g	Other expenses	49.88	57.27	57.95	152.65	154.67	218.17
	Total Expenses	435.37	491.08	427.75	1,491.71	1,251.15	1,536.65
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	4.98	7.14	-43.18	35.73	-130.37	-179.82
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	4.98	7.14	-43.18	35.73	-130.37	-179.82
6	Exceptional Items	-	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	4.98	7.14	-43.18	35.73	-130.37	-179.82
8	Tax Expenses	-	-	-	-	-	-
9	Profit (loss) for the period from continuing operations (7-8)	4.98	7.14	-43.18	35.73	-130.37	-179.82
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit (loss) for the period (9+12)	4.98	7.14	-43.18	35.73	-130.37	-179.82
14	Other Comprehensive Income	0.02	0.35	0.06	3.57	3.80	3.73
	Total Comprehensive Income	5.00	7.49	-43.12	39.30	-126.56	-176.09
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital						
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share	0.17	0.25	-1.44	1.31	-4.22	-5.87
ii	Diluted earnings per share	0.17	0.25	-1.44	1.31	-4.22	-5.87

NOTES ->

- Results for the quarter ended on 31st December, 2025 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 14th February, 2026. The Statutory Auditors carried out the limited review for quarter ended 31st December, 2025. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2025 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech LimitedBrij Raj Gupta
Director
DIN NO. 06974969
Date: 14.02.2026
Place: Delhi



EC69C

**BRAWN BIOTECH LTD.**

BRAWN BIOTECH LIMITED

CIN-L74899DL1985PLC022468

REGD. OFFICE/REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and nine month ended 31st December 2025

(Rs. In Lacs)

Sr. No	Particulars	Standalone					
		Quarter Ended			Nine Months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.09.2025
		Un-audited	Unaudited	Un-audited	Un-audited	Un-audited	Audited
1	Total income from operation	431.26	489.10	384.48	1,500.13	1,170.57	1,346.50
2	Net Profit/(Loss) from ordinary activities after tax	4.56	7.14	-43.18	35.73	-130.37	-179.82
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	4.98	7.14	-43.18	35.73	-130.37	-179.82
4	Total Comprehensive Income [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	5.00	7.49	-43.12	39.30	-126.56	-176.09
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)	-	-	-	-	-	-
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)						
	(a) Basic (Rs.)	0.17	0.25	-1.44	1.31	-4.22	-5.87
	(b) Diluted (Rs.)	0.17	0.25	-1.44	1.31	-4.22	-5.87
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)						
	(a) Basic (Rs.)	0.17	0.25	-1.44	1.31	-4.22	-5.87
	(b) Diluted (Rs.)	0.17	0.25	-1.44	1.31	-4.22	-5.87

NOTES:-

The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-02-2025.
- The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974989

Place: Delhi
Date : 14.02.2026**BRAWN BIOTECH LTD.****CIN NO. : L74899DL1985PLC022468****Works :** Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIAEmail: distribution@brawnbiotech.com | Website : www.brawngroup.in**Regd. Office :** C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331Email: solution@brawnbiotech.com

...for better life



RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of Brawn Biotech Limited for the quarter and Nine Month ended on 31st December 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N


Rajeev Jain
(Partner)



Membership No. 099767
UDIN: 26099767SKQZAL5754


Place: Delhi
Date: 14-02-2026

**CFO CERTIFICATE UNDER REGULATION 33 (2) (a) OF SEBI (LODR)
REGULATION, 2015**

To
The Board of Directors
Brawn Biotech Limited
First Floor, C-64 Lajpat Nagar-1,
South Delhi, Delhi, India, 110024.

- A. We have reviewed Unaudited Financial Results of Brawn Biotech Limited for the quarter ended 31st December 2025 and to the best of our knowledge and belief that;
- a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
- b) These statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of my knowledge and belief, no transaction entered into by the listed entity during the quarter ended 31st December, 2025 which are fraudulent, illegal or violative of the listed entity's code of conduct.
- C. We have indicated to the Auditors and the Audit Committee that there are no significant changes in internal control over financial reporting during the quarter and no instances of significant fraud with which they have become aware.

For Brawn Biotech Limited



Rati Garg
Chief Financial Officer

Date: 09.02.2026

Place: New Delhi



2EC86



BRAWN BIOTECH LTD.

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF BRAWN BIOTECH LIMITED HELD ON SATURDAY, 14th FEBRUARY 2026 AT ITS REGISTERED OFFICE SITUATED AT C-64, LAJPAT NAGAR-1, NEW DELHI-110024, WHICH COMMENCED AT 1.30 P.M AND CONCLUDED AT 2.00 P.M.

APPROVAL UNAUDITED FINANCIAL RESULTS FOR QUARTER 31.12.2025.

The quarterly Unaudited Financial Results of the Company for the quarter ended 31.12.2025 was placed before the board pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, duly reviewed by the Audit Committee along with the Auditors' Review Report. The same was discussed and following resolution was passed unanimously:

"RESOLVED THAT Unaudited Quarterly Financial Results of the Company for the quarter and half year ended 31.12.2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015), duly reviewed by the Audit Committee on which the Review Report has been received, as detailed here in under below be and hereby approved and noted by the Board.

RESOLVED FURTHER THAT Mr. Brij Raj Gupta, Director of the Company be and is hereby authorized to sign the same on behalf of the Board of Directors."

"Further, the "Limited Review Report" in respect of Unaudited Financial Results of the Company for the Quarter ended 31.12.2025 duly reviewed in the Audit Committee Meeting of the Company, given by the Auditor of the Company, was placed before the Board and considered."

**For and on behalf of
Brawn Biotech Limited.**

**Priyanka Sharma
Company Secretary
Membership No. A50385**



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in

...for better life